Home / Generics / Research

Research

Poland’s experience with generic imatinib

In July 2014, Poland became the first country in the European Union (EU) to introduce a generic form of the chronic myeloid leukaemia (CML) treatment imatinib. This, and the dearth of reliable information related to CML patients in Europe who have taken generic imatinib, make the country uniquely positioned to monitor the process of switching from the brand-name drug to its generic, according to author Patrycja Rusicka of the Medical University of Warsaw, Poland [1].

Generic imatinib non-inferior to Gleevec

Following the approval of four generics of imatinib in Turkey, Demirkan and co-authors from the Dokuz Eylül University in Turkey compared the efficacy of these newly approved generics with the originator product Gleevec from Novartis [1].

Proposals to lessen the shortage of essential cancer drugs, generics and biosimilars in the US and the world

Essential cancer and supportive drug shortage in the US seriously affects cancer care, and increases cost pressure on the health system. These drugs are mostly off-patent generics. Collaborative efforts of FDA, pharmacists, physicians and pharmaceutical companies slightly improve this problem. However, these measures are partial. For an issue of multiple complexities there is no single magic stick that could solve it. The underlying economic issues and lack of incentives for production need to be addressed to arrive at innovative and permanent solutions for this multifactorial problem [1, 2].

Effect of price caps and reference pricing on generics entry

In a study carried out by Brekke and co-authors on the impact of price caps in combination with reference pricing on generics entry was investigated [1].

Effect of co-insurance and reference pricing on generics entry

To study the impact of reference pricing on generics entry Brekke and co-authors developed a novel Salop-type model where a brand-name producer competes with several generics makers in terms of prices [1].

Effect of reference pricing on generics entry

Reference pricing can produce substantial savings, but what conditions are the most likely to result in cost savings? This was a question addressed by Brekke and co-authors from the University of Minho in Portugal in their Working Paper [1].

Malaysian physicians have negative perceptions of generics

A study investigating the knowledge, perceptions and behaviour of physicians from private medical centres in Malaysia regarding generics found that the majority of physicians had negative perceptions about the safety, quality and efficacy of generics [1].

Drug evergreening strategies in India

A study of drug patent evergreening in India found that this is a strategy that has been used by manufacturers of a particular drug to restrict or prevent competition from manufacturers of generic equivalents. It is also a strategy still being used in India despite the efforts of Section 3(d) of the Indian Patent Act to curb such practices [1].

Physicians’ perceptions of HIV generics in France

A study of French physicians in HIV clinics found that, while the majority of these physicians were willing to prescribe antiretroviral generics, a quarter of physicians were openly opposed to antiretroviral generics [1].

Patients’ perceptions of HIV generics in France

In a study of patient perceptions of HIV generics in France, Jacomet and co-authors found that while the majority of patients accepted antiretroviral generics, a third of the patients were openly opposed to antiretroviral generics [1].

Generics News Research General

more

Biosimilars News Research General

more